Beam Therapeutics (BEAM) Income from Continuing Operations (2019 - 2026)
Beam Therapeutics (BEAM) reported Income from Continuing Operations of 97348000.0 for Q1 2026, up 11.03% year-over-year from 87673774.08 in Q1 2025, and down 139.85% quarter-over-quarter from 244297000.0 in Q4 2025.
Beam Therapeutics (BEAM) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Beam Therapeutics (BEAM) has 8 years of Income from Continuing Operations data on file, last reported at 97348000.0 in Q1 2026.
- Income from Continuing Operations for Q1 2026 came in at 97348000.0, up 11.03% year-over-year; the trailing twelve-month figure through Mar 2026 was 68070000.0 (up 82.43% YoY), and the FY2025 annual result was 79992000.0, up 78.77% from the prior year.
- Income from Continuing Operations slipped to 97348000.0 in Q1 2026 per BEAM's latest filing, from 244297000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 244297000.0 in Q4 2025 and troughed at 112728000.0 in Q3 2025.
- A 5-year average of 55931588.24 and a median of 90354000.0 in 2024 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2023: Income from Continuing Operations slumped 199.01% in 2022, then soared 472.18% in 2023.
- A 5-year view of Income from Continuing Operations shows it stood at 38359000.0 in 2022, then soared by 472.18% to 142763000.0 in 2023, then plunged by 163.29% to 90354000.0 in 2024, then surged by 370.38% to 244297000.0 in 2025, then plunged by 139.85% to 97348000.0 in 2026.
- Business Quant data shows BEAM's Income from Continuing Operations at 97348000.0 in Q1 2026, 244297000.0 in Q4 2025, and 112728000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Beam Therapeutics | 3.53 Bn | 3.53 Bn | - | -97.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -97.35 Mn |
| Dec 31, 2025 | 244.30 Mn |
| Sep 30, 2025 | -112.73 Mn |
| Jun 30, 2025 | -102.29 Mn |
| Mar 31, 2025 | -109.42 Mn |
| Dec 31, 2024 | -90.35 Mn |
| Sep 30, 2024 | -96.67 Mn |
| Jun 30, 2024 | -91.05 Mn |
| Mar 31, 2024 | -92.28 Mn |
| Dec 31, 2023 | 142.76 Mn |
| Sep 30, 2023 | -96.09 Mn |
| Jun 30, 2023 | -82.78 Mn |
| Mar 31, 2023 | -88.97 Mn |
| Dec 31, 2022 | -38.36 Mn |
| Sep 30, 2022 | -84.08 Mn |
| Jun 30, 2022 | -79.91 Mn |
| Mar 31, 2022 | -75.58 Mn |
| Dec 31, 2021 | -64.71 Mn |
| Sep 30, 2021 | -28.12 Mn |
| Jun 30, 2021 | -59.03 Mn |